Key Dates

Related Announcements

• November 04, 2024 - Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional). See NOFO RFA-DA-26-018.
• November 04, 2024 - Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional). See NOFO RFA-DA-26-019.

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Guide Notice is to inform potential applicants regarding correction to the due date of RFA-DA-26-018 “Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)” and increase of the award budget for RFA-DA-26-018 “Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)” and RFA-DA-26-019 “Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)”

RFA-DA-26-018 Currently Reads:

Key Dates

Applications Due Date

New

Not applicable

RFA-DA-26-018 Modified to Read (in bold):

Key Dates

Applications Due Date

New

February 19, 2025

RFA-DA-26-018 and RFA-DA-26-019 Currently Reads:

Part 2. Full Text of Announcement
Section II. Award Information
Award Budget

Budgets up to $306,872 total costs for Phase I and up to $2,045,816 total costs for Phase II may be requested

RFA-DA-26-018 and RFA-DA-26-019 Modified to Read (in bold):

Part 2. Full Text of Announcement
Section II. Award Information
Award Budget

Budgets up to $314,363 total costs for Phase I and up to $2,095,748 total costs for Phase II may be requested

All other aspects of this NOFO remain unchanged.

Inquiries

Please direct all inquiries to:

Yordan Kostov, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-5650
Email: [email protected]